arrow
A

Alessio Cortellini

Università Campus Bio-Medico di Roma
H指数:51
被引数:9,240

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venous thromboembolism reporting in fusion-positive NSCLC treated with tyrosine kinase inhibitors: A systematic review of safety reporting and protocol-level provisions in phase I-IV clinical trials

酪氨酸激酶抑制剂治疗融合阳性非小细胞肺癌中的静脉血栓栓塞事件报告:一项关于安全性报告和方案级规定在I-IV期临床试验的系统综述

2026-10-270
OAAI
Chemotherapy Backbone and Outcomes of Immune Checkpoint Inhibitor Combinations Across Solid Tumors: A Pan-Tumor Network Meta-Analysis

化疗基础方案与免疫检查点抑制剂联合疗法在实体瘤中的疗效:一项泛肿瘤网络Meta分析

2026-09-170
OAAI
Broad baseline-variable profiling of visceral conversion in bone-only HR+/ HER2-metastatic breast cancer treated with CDK4/6 inhibitors

骨转移性HR+/HER2-转移性乳腺癌经CDK4/6抑制剂治疗后腹腔转化的大范围基线-变量分析

2026-09-011
OA
Artificial intelligence for bone metastases: a systematic review and meta-analysis of diagnostic and prognostic performance

人工智能在骨转移中的应用:诊断和预后效能的系统评价与Meta分析

2026-08-300
OA
Skeletal metastatic burden as a strong prognostic factor of survival in advanced NSCLC treated with chemo-immunotherapy: An exploratory imaging-based analysis

骨转移负荷作为接受化疗-免疫治疗晚期非小细胞肺癌生存的强预后因素:一项基于影像学的探索性分析

2026-08-010
OAAI
Effectiveness and safety of immunotherapy in advanced NSCLC with pericardial effusions: a global retrospective multicenter study

免疫疗法在伴有心包积液的晚期NSCLC中的有效性和安全性:一项全球回顾性多中心研究

2026-07-250
OAAI
Response to Letter Re: Real-World Outcomes of Immunotherapy Discontinuation at Two Years in Advanced Non-Small Cell Lung Cancer: final results of the ISTOP study.

回复函:关于晚期非小细胞肺癌免疫疗法停药两年后的真实世界结局:ISTOP研究的最终结果。

2026-05-020
PRE
Late endocrine-metabolic complications in survivors of young adult and adult-onset cancers: comprehensive evaluation and strategies for management. An Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical review

年轻成年及成年发病癌症幸存者的晚期内分泌-代谢并发症:全面评估与管理策略。意大利医学肿瘤学会(AIOM)、意大利医学糖尿病学会(AMD)、意大利糖尿病学会(SID)、意大利内分泌学会(SIE)、意大利药理学学会(SIF)多学科批判性综述

2025-12-030
OAAI
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

长期接受帕博利珠单抗单药治疗的患者中,具有晚期非小细胞肺癌、PD-L1表达≥50%且体力状况较差者的长期结局:基于Transformer的AI用于表征预后复杂性

2025-10-160
OAAI
Probiotic supplement exposure and outcomes of patients with non-small cell lung cancer treated with first-line atezolizumab therapy: Pooled analysis of individual patient data from five randomized control trials

益生菌补充剂暴露与非小细胞肺癌患者接受一线阿替利珠单抗治疗后的结局:基于五项随机对照试验个体患者数据的合并分析

2025-10-100
PRE
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

一线免疫治疗联合或不联合化疗与BRAF联合MEK抑制剂在BRAFV600E突变型转移性非小细胞肺癌中的比较(FRONT-BRAF):一项多中心、回顾性队列研究

2025-09-290
PRE
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis

铂类化疗和CTLA-4抑制对非小细胞肺癌中一线抗PD-1/PD-L1药物获得性耐药的影响:一项系统综述和重构的个体患者数据分析

2025-09-020
PREAI
The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation

传统及人工智能基础的临床预测模型在非小细胞肺癌中的研究进展:从模型构建到真实世界验证

2025-08-200
PREAI
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma

肺大细胞神经内分泌癌的整合分子与临床特征分析

2025-08-190
OA